tofacitinib

tofacitinib is a medication belonging to the class of drugs known as Janus kinase inhibitors. It is primarily used in the treatment of several autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis. Developed by Pfizer, it functions by modulating the immune system through the inhibition of specific enzyme pathways. Its approval by regulatory bodies like the U.S. Food and Drug Administration marked a significant advancement in the therapeutic options for inflammatory diseases.

Medical uses

Tofacitinib is indicated for the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response to methotrexate or other disease-modifying antirheumatic drugs. It is also approved for active psoriatic arthritis, often in combination with non-biologic DMARDs, and for moderate to severe ulcerative colitis. Additionally, it is used for ankylosing spondylitis in adults. Clinical trials, such as those published in *The New England Journal of Medicine*, have demonstrated its efficacy in reducing disease activity and improving physical function. The American College of Rheumatology includes it in treatment guidelines for several conditions.

Adverse effects

Common adverse effects include upper respiratory tract infection, headache, diarrhea, and nasopharyngitis. More serious risks involve an increased incidence of serious infections, such as tuberculosis and opportunistic infections, due to its immunosuppressive action. The Food and Drug Administration has issued a black box warning for the risks of serious infections, malignancy including lymphoma, and thrombosis such as pulmonary embolism and deep vein thrombosis. Other concerns include gastrointestinal perforation and changes in laboratory test results like neutropenia and dyslipidemia.

Pharmacology

Tofacitinib acts as a potent and selective inhibitor of Janus kinase enzymes, particularly JAK1 and JAK3, which are involved in cytokine signaling pathways critical for immune response and inflammation. By inhibiting the JAK-STAT signaling pathway, it reduces the production of inflammatory mediators like interleukin-2, interleukin-4, interleukin-7, interleukin-9, interleukin-15, and interleukin-21. It is administered orally and undergoes hepatic metabolism primarily via the cytochrome P450 system, specifically CYP3A4, with a minor role for CYP2C19. Its pharmacokinetics can be affected by coadministration with strong CYP3A4 inhibitors or inducers.

History

The development of tofacitinib originated from research at Pfizer's laboratories in Groton, Connecticut, focusing on small molecule inhibitors of Janus kinases. Key phase III clinical trials, known as the ORAL studies, were conducted globally and reported in journals like *The Lancet*. The Food and Drug Administration first approved it for rheumatoid arthritis in 2012, followed by expanded indications for psoriatic arthritis in 2017 and ulcerative colitis in 2018. The European Medicines Agency granted marketing authorization in the European Union under the name Xeljanz. Post-marketing studies, such as the ORAL Surveillance trial, led to updated safety warnings from regulatory agencies.

Society and culture

Tofacitinib is marketed under the brand name Xeljanz by Pfizer and is available as a generic medication in some regions. It has been the subject of significant discussion at medical conferences like the American College of Rheumatology Annual Meeting and the European League Against Rheumatism congress. Its cost and insurance coverage have been points of debate within healthcare systems, including discussions by organizations like the National Institute for Health and Care Excellence in the United Kingdom. The drug's development is considered a milestone in the field of immunology and has influenced research into other JAK inhibitors such as baricitinib and upadacitinib.

Category:Drugs